Работы, на которые ссылается эта работа

Работ: 199

Работа: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao +3
Обзорная статья2023Цитирований: 6
ABI
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao, Shengkang Huang, Sifei Chen +4
Обзорная статья2021Цитирований: 5
ABI
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen +5
Статья2024Цитирований: 5
ABI
Exploring treatment options in cancer: tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan +2
Обзорная статья2024Цитирований: 5
ABI
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang +2
Обзорная статья2024Цитирований: 5
ABI
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4
Статья2017Цитирований: 4
ABI
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6
Статья2017Цитирований: 4
ABI
CAR-T Cell Performance: How to Improve Their Persistence?
Gina López-Cantillo, Claudia Urueña, Bernardo Camacho +1
Обзорная статья2022Цитирований: 4
ABI
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Miyuki Tanaka, Haruko Tashiro, Bilal Omer +9
Статья2017Цитирований: 3
ABI
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18
Статья2017Цитирований: 3
ABI
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong, Justin Clubb, Yvonne Y. Chen
Обзорная статья2020Цитирований: 3
ABI
Bispecific T‐cell engagers for cancer immunotherapy
Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman
Обзорная статья2014Цитирований: 3
ABI
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Andriy Marusyk, Michalina Janiszewska, Kornélia Polyák
Обзорная статья2020Цитирований: 3
ABI
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12
Статья2021Цитирований: 3
ABI
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang, Na Li, Kaichao Feng +14
Статья2021Цитирований: 3
ABI
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Changsong Qi, Jifang Gong, Jian Li +23
Статья2022Цитирований: 3
ABI
Long-term outcomes following CAR T cell therapy: what we know so far
Kathryn M. Cappell, James N. Kochenderfer
Обзорная статья2023Цитирований: 3
ABI
Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases
Agata Kieliszek, Daniel Mobilio, Deepak Upreti +10
Статья2023Цитирований: 3
ABI
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown, Behnam Badie, Michael E. Barish +14
Статья2015Цитирований: 2
ABI
Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Serena Perna, Daria Pagliara, Aruna Mahendravada +4
Статья2013Цитирований: 2
ABI
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta +11
Статья2016Цитирований: 2
ABI
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
Lenka V. Hurton, Harjeet Singh, Amer Najjar +12
Статья2016Цитирований: 2
ABI
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser, Leonid Cherkassky, Navin K. Chintala +1
Обзорная статья2019Цитирований: 2
ABI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9
Статья2013Цитирований: 2
ABI
The inducible caspase-9 suicide gene system as a â€œsafety switchâ€ to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Tessa Gargett, Michael P. Brown
Обзорная статья2014Цитирований: 2
ABI